Virus vectors are the tools by which scientists deliver harmless, modified versions of viruses to human cells. As the functional genetic material within vaccines, they perform the critical function of instructing cells to recognize and fight diseases, including viruses.
The rush to develop a vaccine for coronavirus confirmed this challenge. Manufacturers struggled to produce membrane filters to purify viral vectors and virus-like particles, primarily because of capacity and fouling of membranes, which caused delays in vaccine production. Robust membrane performance under a range of operating conditions also led to production delays.
For this project, researchers led by Qian will create a scalable, downstream manufacturing platform for purification that will replace the standard processes of centrifugation and resin-based chromatography, both of which are difficult to scale up in manufacturing.
The project will require feedstock production of two common viral vectors for gene-therapy, virus-like particles for vaccine applications and advanced microfiltration for bioreactor harvesting. The researchers will design, fabricate and characterize high-capacity membranes and will develop membrane chromatography for separating full and empty viral capsids.
The researchers will use state-of-the-art bioanalytical methods for detection and quantification and will develop a readiness and acceptance study to help drive the technology toward commercial production.
The Arkansas researchers co-principal investigators Bob Beitle, professor of chemical engineering; Ranil Wickramasinghe, Distinguished Professor of chemical engineering; and several others, in addition to Qian will collaborate with researchers at the University of Kentucky and Clemson University.
In addition to the significant human impact, the project will bring economic benefits to Arkansas, Kentucky and South Carolina, where regional incubator centers for biotechnology development will be established.